Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15442198 | 0.83 | ALDH1A1 (0.40) | ALDH1A1PKMMITFSOS1KMT2A | |
| SCHEMBL13281114 | 0.83 | ALDH1A1 (0.40) | ALDH1A1PKMMITFSOS1KMT2A | |
| SCHEMBL13280994 | 0.83 | ALDH1A1 (0.40) | ALDH1A1PKMMITFSOS1KMT2A | |
| SCHEMBL1228029 | 0.80 | ALDH1A1 (0.36) | ALDH1A1PKMMITFSOS1KMT2A | |
| SCHEMBL1228719 | 0.78 | ALDH1A1 (0.43) | ALDH1A1PKMMITFSOS1KMT2A | |
| SCHEMBL30576258 | 0.75 | ALDH1A1 (0.46) | ALDH1A1PKMMITFSOS1KMT2A | |
| SCHEMBL28574994 | 0.75 | ALDH1A1 (0.49) | ALDH1A1PKMMITFSOS1KMT2A | |
| SCHEMBL28570815 | 0.74 | ALDH1A1 (0.47) | ALDH1A1PKMMITFSOS1KMT2A | |
| SCHEMBL1227172 | 0.73 | ALDH1A1 (0.44) | ALDH1A1PKMMITFSOS1KMT2A | |
| SCHEMBL1227163 | 0.73 | ALDH1A1 (0.41) | ALDH1A1PKMMITFSOS1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293734-B2 | Nitroimidazooxazine and nitroimidazooxazole analogues and their uses | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-10-23 | — | — | US | disclosed |
| CN-102741259-A | Nitroimidazooxazine and nitroimidazooxazole analogues and uses thereof | GLOBAL ALLIANCE FOR TB DRUG DEV | 2012-10-17 | — | — | CN | disclosed |
| US-20110028466-A1 | NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028466-A1 | NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES | NOX5, NQO2, SIRT5 | ALDH1A1 2444/4885PKM 1709/4885MITF 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.